Insmed Incorporated (NASDAQ:INSM) Expected to Announce Earnings of -$0.59 Per Share

Analysts forecast that Insmed Incorporated (NASDAQ:INSM) will announce ($0.59) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Insmed’s earnings. The lowest EPS estimate is ($0.68) and the highest is ($0.47). Insmed posted earnings of ($0.94) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 37.2%. The company is expected to issue its next earnings report on Tuesday, May 5th.

On average, analysts expect that Insmed will report full-year earnings of ($2.23) per share for the current fiscal year, with EPS estimates ranging from ($2.53) to ($1.89). For the next fiscal year, analysts expect that the company will post earnings of ($1.40) per share, with EPS estimates ranging from ($2.26) to ($0.08). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Insmed.

Insmed (NASDAQ:INSM) last announced its earnings results on Tuesday, February 25th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.01). The company had revenue of $45.70 million during the quarter, compared to analysts’ expectations of $45.06 million. Insmed had a negative return on equity of 94.35% and a negative net margin of 186.37%. The company’s revenue was up 366.3% compared to the same quarter last year.

Several research firms have weighed in on INSM. Credit Suisse Group reissued an “outperform” rating and issued a $40.00 price target on shares of Insmed in a research note on Thursday, January 2nd. BidaskClub raised shares of Insmed from a “sell” rating to a “hold” rating in a research note on Wednesday, February 5th. HC Wainwright reissued a “buy” rating and issued a $52.00 price target on shares of Insmed in a research note on Tuesday, February 4th. Goldman Sachs Group boosted their price target on shares of Insmed from $33.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, February 4th. Finally, Zacks Investment Research raised shares of Insmed from a “sell” rating to a “hold” rating in a research note on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Insmed has an average rating of “Buy” and a consensus price target of $41.25.

Insmed stock opened at $24.20 on Tuesday. The company has a quick ratio of 6.70, a current ratio of 6.97 and a debt-to-equity ratio of 1.19. The company has a market capitalization of $2.36 billion, a PE ratio of -7.96 and a beta of 3.12. The firm has a fifty day simple moving average of $26.35 and a two-hundred day simple moving average of $21.33. Insmed has a twelve month low of $15.33 and a twelve month high of $34.94.

A number of institutional investors have recently bought and sold shares of INSM. Geode Capital Management LLC raised its stake in shares of Insmed by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 1,215,211 shares of the biopharmaceutical company’s stock valued at $29,019,000 after acquiring an additional 46,915 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Insmed by 11.0% during the fourth quarter. Alliancebernstein L.P. now owns 118,700 shares of the biopharmaceutical company’s stock valued at $2,835,000 after acquiring an additional 11,800 shares during the last quarter. AXA bought a new position in shares of Insmed during the fourth quarter valued at about $4,081,000. UBS Asset Management Americas Inc. grew its holdings in Insmed by 1.8% in the fourth quarter. UBS Asset Management Americas Inc. now owns 89,873 shares of the biopharmaceutical company’s stock worth $2,146,000 after purchasing an additional 1,581 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in Insmed by 57.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 929,284 shares of the biopharmaceutical company’s stock worth $22,191,000 after purchasing an additional 340,472 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE┬« (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Recommended Story: What is Liquidity?

Get a free copy of the Zacks research report on Insmed (INSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.